Invivyd, Inc. Common Stock

IVVDNASDAQUSD
1.03 USD
0.08 (7.21%)AT CLOSE (11:59 AM EDT)
1.04
0.01 (0.97%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
1.04
0.01 (0.97%)
🔴Market: CLOSED
Open?$1.13
High?$1.13
Low?$0.99
Prev. Close?$1.11
Volume?5.0M
Avg. Volume?2.8M
VWAP?$1.04
Rel. Volume?1.75x
Bid / Ask
Bid?$1.03 × 400
Ask?$1.07 × 800
Spread?$0.04
Midpoint?$1.05
Valuation & Ratios
Market Cap?303.4M
Shares Out?294.6M
Float?155.5M
Float %?66.7%
P/E Ratio?N/A
P/B Ratio?1.49
EPS?-$0.26
Dividend?0.00%
Ex-Dividend?N/A

IVVD is currently priced at $1.03. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest IVVD is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
Employees
122
Market Cap
303.4M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2021-08-06
Address
209 CHURCH STREET
NEW HAVEN, CT 06510
Phone: (781) 819-0080
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-2/3)
Medium-Term (Wave)? Bearish(-1/3)
Short-Term (Ripple)? Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
1
Momentum?
97
Short Sent.?
20
Piotroski F-Score?2/9Weak
Altman Z-Score?-1.09Distress
Confidence?51%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?19.98%High
Short Interest?31.1M
Days to Cover?9.5
Free Float155.5M
Avg Daily Volume3.3M
Settlement Date2026-05-15
Financial Health
Current Ratio?6.47Strong
Quick Ratio?6.47Strong
Cash Ratio?5.82Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
92/100
P/E?
N/A
P/B?
Peers
100
S&P
87
1.49CHEAP
P/S?
Peers
100
S&P
26
5.43FAIR
P/FCF?
N/A
EV/EBITDA?
S&P
97
-1.5CHEAP
EV/Sales?
Peers
100
S&P
73
2.14CHEAP
Returns & Efficiency
ROE?
S&P
3
-38.2%WEAK
ROA?
S&P
3
-32.1%WEAK
Cash Flow & Enterprise
FCF?$-79455000
Enterprise Value?$119.3M
Fundamentals ratios updated end of day